Novavax announced extended durability of protection against infection and disease in UK COVID-19 vaccine phase 3 clinical Trial
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
Sanofi and GSK announced regulatory authorization for COVID-19 vaccine
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
Moderna and Thermo Fisher Scientific announced long-term strategic collaboration
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…
Novavax announced shipments of COVID-19 vaccine to European Union member states
On Feb. 23, 2022, Novavax announced the first doses of Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) had begun shipping…
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine | WHO
Sorrento announced COVISHIELD antibody strongly neutralized BA.2 Omicron sublineage virus
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
Moderna expanded global footprint through commercial partnership with Adium in Latin America
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
Novavax and Serum Institute of India announced first EUA of COVID-19 vaccine in adolescents =12 to <18 in India
On Mar. 22, 2022, Novavax and Serum Institute of India announced that the Drugs Controller General of India…
WHO announced first technology recipients of mRNA vaccine hub
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
CDC released the 2022 recommended immunization schedules for children and adolescents, as well as for adults
On Feb. 18, 2022, the U.S. Centers for Disease Control and Prevention (CDC) released the 2022 recommended immunization…
Health Canada authorized Novavax COVID-19 vaccine
On Feb. 17, 2022, Novavax announced that Health Canada had granted authorization for Nuvaxovid COVID-19 Vaccine (Recombinant protein,…
Resverlogix expanded phase 2b clinical trial for COVID-19 treatment with first site in Brazil and second in Canada
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
Therapeutic Goods Administration of Australia authorized Moderna’s Covid-19 vaccine in children (6-11 Years)
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
BioNTech introduced first modular mRNA manufacturing facility to promote scalable vaccine production in Africa
On Feb. 16, 2022, BioNTech announced it had introduced its approach to establishing scalable vaccine production by developing…
European Medicines Agency approved Pfizer’s 20-valent pneumococcal conjugate vaccine
On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyﾒs 20-valent pneumococcal conjugate…
Singapore Health Sciences Authority issued interim authorization for Novavax COVID-19 vaccine
On Feb. 14, 2022, Novavax announced that the Singapore Health Sciences Authority (HSA) had issued interim authorization for…
Novavax files for conditional Marketing Authorization of COVID-19 vaccine in Switzerland
On Feb. 14, 2022, Novavax announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional…
Novavax announced positive results of COVID-19 vaccine in pediatric population of PREVENT-19 phase 3 clinical trial
On Feb. 10, 2022, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness…
Research scientists identified vulnerable site on multiple coronaviruses that could be targeted to prevent future pandemics.
On Feb. 10, 2022, Scripps Research announced that the COVID-causing virus SARS-CoV-2 harbors a vulnerable site at the…
Moderna announced new supply agreement with Colombia for additional 10.8 million doses of COVID-19 vaccine
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
Study suggested COVID-19 vaccines do not reduce fertility
On Feb. 8, 2022, a research team led at Boston University School of Public Health reported on links…
CDC’s ACIP issued recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Life Science History | Medicine | NIH | Non-Profit Research | Therapeutics | Vaccine
Cancer MoonShot program reignited
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
Moderna received full U.S. FDA approval for COVID-19 vaccine Spikevax
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA) had approved the Biologics License…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
Novavax and Israel announced advance purchase agreement for supply of COVID-19 vaccine
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
WHO and Viamo provided critical access to COVID-19 information to the next billion digital users via their mobile phones
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoﾒs 3-2-1 Platform…
Moderna announced first participant dosed in phase 2 study of Omicron-specific booster candidate and publication of data
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
International research team found nine new coronavirus species
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…